Brief: Promore Pharma: Positive Phase IIb Study Results Of Ropocamptide In Venous Leg Ulcers

PMD Device Solutions AB

19/11/2020 13:40

Nov 19 (Reuters) - Promore Pharma AB  PROMO.ST :
    * PROMORE PHARMA ANNOUNCES POSITIVE RESULTS FROM PHASE IIB STUDY OF ROPOCAMPTIDE IN THE
TREATMENT
OF VENOUS LEG ULCERS
    * STUDY SHOW THAT LARGER WOUNDS (≥10CM2) HEALED SIGNIFICANTLY FASTER AMONG PATIENTS TREATED
WITH
ROPOCAMPTIDE AS COMPARED WITH PLACEBO.
    * AT AN AGGREGATED LEVEL, WHERE WOUNDS OF ALL SIZES INCLUDED IN STUDY WERE ANALYZED, NO
SIGNIFICANT DIFFERENCES CAN BE NOTED AT WHOLE GROUP LEVEL BETWEEN THREE TREATMENT GROUPS.
    * NO SERIOUS SIDE EVENTS HAVE BEEN NOTED THAT CAN BE CONSIDERED RELATED TO TRIAL DRUG.

Source text: https://bit.ly/32YutG2
Further company coverage:  PROMO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))